Propranolol ( DrugBank: Propranolol )

5 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
158	Tuberous sclerosis	1
167	Marfan syndrome	1
227	Osler disease	1
278	Huge lymphatic malformation with cervicofacial lesion	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-004629-18-NL (EUCTR)	13/04/2017	17/01/2017	The influence of stress on Parkinson's tremor	The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach - Noradrenergic basis of Parkinson tremor	Tremor in Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Propranolol Product Name: Propranolol HCl CF 40 mg tablet Product Code: RVG 55618	Radboud University Nijmegen	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 3	Netherlands

Clinical trials : 112 / Drugs : 71 - (DrugBank : 19) / Drug target genes : 35 - Drug target pathways : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02104011 (ClinicalTrials.gov)	May 22, 2015	1/4/2014	Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers	Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial	Renal Angiomyolipomas;Tuberous Sclerosis	Drug: Propranolol	University Hospital, Bordeaux	NULL	Completed	18 Years	N/A	All	2	Phase 2	France

Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00651235 (ClinicalTrials.gov)	February 2007	3/3/2008	A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome	A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome	Marfan Syndrome	Drug: Losartan and Atenolol or Propranolol;Drug: Atenolol or Propranolol	National Taiwan University Hospital	NULL	Recruiting	1 Year	N/A	Both	44	Phase 2	Taiwan

Clinical trials : 56 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04113187 (ClinicalTrials.gov)	June 23, 2020	27/9/2019	Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients	Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients	Hereditary Hemorrhagic Telangiectasia;Osler Weber Rendu Disease	Drug: Propranolol treatment;Drug: Placebo	University Hospital, Bordeaux	AMRO-HHT-France - Association Maladie de Rendu-Osler	Completed	18 Years	N/A	All	15	Phase 3	France

Clinical trials : 19 / Drugs : 22 - (DrugBank : 7) / Drug target genes : 5 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008498	2012/07/25	24/07/2012	Propranolol for a treatment of lymphatic malformation	Propranolol for a treatment of lymphatic malformation - Propranolol study for lymphatic malformation	lymphatic malformation	propranolol therapy	University of Tokyo	NULL	Complete: follow-up complete	Not applicable	65years-old	Male and Female	20	Phase 2	Japan